Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.08K Hold
33
﹤0.01% 2676
2026
Q1
$1.17K Hold
33
﹤0.01% 2511
2025
Q4
$1.34K Hold
33
﹤0.01% 2547
2025
Q3
$1.55K Hold
33
﹤0.01% 2420
2025
Q2
$1.72K Hold
33
﹤0.01% 2337
2025
Q1
$1.99K Hold
33
﹤0.01% 2359
2024
Q4
$2.26K Hold
33
﹤0.01% 2192
2024
Q3
$2.37K Buy
+33
New +$2.33K ﹤0.01% 2153
2024
Q2
Sell
-33
Closed -$2.64K 1795
2024
Q1
$2.64K Buy
+33
New +$2.94K ﹤0.01% 2064
2022
Q4
$2.92K Buy
+33
New +$2.74K ﹤0.01% 1864
2022
Q3
Sell
-33
Closed -$3K 816
2022
Q2
$3K Buy
+33
New +$3.96K ﹤0.01% 1771
2022
Q1
Sell
-33
Closed -$5K 831
2021
Q4
$5K Buy
+33
New +$4.67K ﹤0.01% 1741

Other funds holding CNMD

CoreCap Advisors's CNMD Position: Q2 2026 in Review

CoreCap Advisors held its CONMED (CNMD) position steady in Q2 2026 at 33 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2676.

CoreCap Advisors first reported a position in CNMD in Q4 2021 and has held it in 12 quarters since. The position peaked at $5K in Q4 2021. 23 funds tracked by Wall St. Rank hold CNMD as of Q2 2026.

  • CoreCap Advisors held 33 shares of CONMED worth $1.08K as of Q2 2026.
  • CoreCap Advisors left its CONMED share count unchanged in Q2 2026.
  • CONMED made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2676 holding.
  • CoreCap Advisors first reported a position in CONMED in Q4 2021 and has held it in 12 quarters since.
  • CoreCap Advisors's CONMED position peaked at $5K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held CONMED as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.